- Surgical masks don't prevent all transmission. We need to up our mask game and use KN95, KF94 or better masks.
2/
- Patients should have private rooms. This would improve infection control, privacy, and the ability of patients to get the rest they need.
3/
- We need universal precautions in hospitals. Staff should be wearing N95 masks and goggles/faceshields regardless of whether the patient is known to have COVID or not.
4/ - Fully vaccinated patients with COVID symptoms should be tested for SARS-CoV-2, isolated, and treated as COVID suspects until proven test negative.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
By making data interoperability easy and affordable, @graphite_health facilitates the rapid adoption of digital health solutions.
.@graphite_health is creating a secure and open digital app marketplace. This will bring significant efficiencies to health systems’ operations, create a more modern & convenient patient experience, & make it easier for digital health entrepreneurs to scale their solutions.
2/ Vaccine effectiveness of 2 doses of Pfizer COVID vaccine VERSUS INFECTION:
- all 12+: 88% in 1st month after vaxx➡️47% after 5 months
- among 65+: 80% in 1st month after vaxx➡️43% after 5 months
3/ Vaccine effectiveness of 2 doses of Pfizer COVID vaccine VERSUS HOSPITALIZATION:
- all 12+: VE vs hospitalization 87% in 1st month after vaxx➡️88% at 5 months
1/ Such an important piece by @edyong209: theatlantic.com/health/archive…
Our health system is broken.
Health system isn't synonymous with healthcare.
The healthcare industry isn't designed to fight pandemics.
2/ We don't value public health in this country. washingtonpost.com/outlook/2020/0…
We don't value PUBLIC in this country.
We don't think we're all in it together.
3/ Health is SOCIAL, not individual.
Biomedical interventions don't fix social problems.
2/ @NIH@NIAIDNews
Phase I/II clinical trial of boosting 12+ weeks
after 2 Moderna, 2 Pfizer, or 1 J&J
- To assess safety & reactogenicity
- To assess the breadth of humoral immune responses clinicaltrials.gov/ct2/show/NCT04…
3/ They're studying all possible combinations:
1 J&J➡️1 Moderna
1 J&J➡️1 J&J
1 J&J➡️1 Pfizer
2 Moderna➡️1 Moderna
2 Moderna➡️1 J&J
2 Moderna➡️1 Pfizer
2 Pfizer➡️1 Moderna
2 Pfizer➡️1 J&J
2 Pfizer➡️1 Pfizer
With follow-up 14d, 28d, 3m, 6m, 12m after the booster dose.
1/ Merck/Ridgeback, Pfizer, & Roche/Atea all have oral antiviral pills for the treatment of COVID in phase II/III clinical trials.
We anticipate results in the next couple of months with submission to the @US_FDA to follow soon thereafter.
But will these be game-changing?
2/ Remdesivir & monoclonal antibodies, both therapeutics for COVID, haven't been game-changing.
It's BEST to prevent COVID with VACCINATION.
But it's good to have COVID therapeutics as a backup measure, especially for older & more vulnerable or immunocompromised people.
3/ COVID drugs work by blocking the machinery that allows the virus to replicate. This reduces the viral load and the duration of infection. But if the damage has already been done, COVID drugs won't reverse that.